A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

September 27, 2017

Study Completion Date

September 27, 2017

Conditions

Type1 Diabetes Mellitus

Interventions

DRUG

BioChaperone® insulin lispro

Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump

DRUG

Fiasp®

Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump

DRUG

Novorapid®

Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump

Trial Locations (1)

Profil Institut für Stoffwechselforschung GmbH, Neuss